라니티딘 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the ranitidine market size is expected to grow from USD 589.15 million in 2025 to USD 613.13 million in 2026 and is forecast to reach USD 762.99 million by 2031 at 4.47% CAGR over 2026-2031.

This report is Segmented by Strength (75 Mg, 150 Mg, 300 Mg), Form (Tablet, Syrup, Injection), Route (Oral, Intravenous), Application (GERD, Peptic Ulcer, ZES, Erosive Esophagitis, Stress Ulcer), Distribution Channel (Hospital, Retail, Online Pharmacies), End User (Hospitals, Clinics, Ascs, Home Care), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Ranitidine Market Trends and Insights

Rising GERD and Peptic Ulcer Burden Structurally Widens the Addressable Patient Pool

Global GERD prevalence grew at an average annual rate of 3.4% from 1990 and reached 825.6 million prevalent cases in 2021. India recorded 36.6 million incident cases in 2021, while China recorded 20.9 million cases. These countries are important to the ranitidine market because cost remains a major consideration in acid suppression therapy. The increasing case load broadens the group of patients who may need treatment for reflux symptoms or ulcer-related conditions. Food patterns and limited reimbursement can make lower-cost therapies more relevant in parts of Southeast Asia and Sub-Saharan Africa. The ranitidine market therefore, retains demand potential where a patient cannot easily move to a higher-cost treatment.

Preference for Low-Cost Acid Suppression in Price-Sensitive Markets Sustains Generic Volume

In out-of-pocket treatment settings, ranitidine remains a lower-cost option rather than a direct substitute for every proton pump inhibitor prescription. The ranitidine market benefits where generic proton pump inhibitors still cost more than an H2 blocker for uninsured patients. Indian manufacturing clusters in Hyderabad and Ahmedabad support the supply of active pharmaceutical ingredients and finished doses to domestic and export markets. Government incentives introduced in 2025 to support domestic production of essential pharmaceutical ingredients reinforce this supply position. Lower-cost production can help Indian suppliers serve Southeast Asia, Africa, and South America without leaving these markets. The ranitidine market remains exposed to price competition, but limited insurance coverage can preserve demand for established generic therapies.

NDMA Recall Legacy and Persistent Trust Deficit Constrain Re-Adoption Rates

The 2020 withdrawal of ranitidine from the United States created a trust barrier that remains relevant after the 2025 approval. The ranitidine market must regain confidence among prescribers and patients who moved to other acid-suppression therapies. The American Gastroenterological Association stated in December 2025 that reformulated ranitidine is unlikely to provide a greater clinical benefit than famotidine. This position reduces the reason to change treatment for patients who are already stable on an alternative. Testing, batch release, and storage controls add cost and complexity for manufacturers serving regulated export markets. The ranitidine market will depend on consistent evidence that new products can manage the impurity risk throughout their shelf life.

Other drivers and restraints analyzed in the detailed report include:

1. Reformulated Products and Impurity-Control Capabilities Reopening Selected Demand Pools
2. Established Oral Dosage Familiarity in Hospital and Retail Formularies
3. Substitution by PPIs and Famotidine-Based Alternatives Restructures the Long-Term Ceiling

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The 150 mg strength commanded 48.71% of the ranitidine market in 2025 and remained the standard dose for many outpatient GERD and maintenance prescriptions. Its use reflects established twice-daily treatment routines for reflux symptoms and peptic ulcer disease. Retail pharmacies and hospitals commonly list this strength as a core dispensing option. The 75 mg strength has a smaller role in selected European and Asian countries where lower-dose products remain available. Its contribution is limited in the European Union because the suspension of ranitidine medicines remains in effect. The Ranitidine industry continues to rely on strength-specific availability in each national market.

The 300 mg segment is forecast to grow at a 6.16% CAGR between 2026 and 2031. This dose supports single bedtime dosing protocols used for some duodenal ulcer patients. Fewer doses may improve adherence in institutional care where medication administration is closely scheduled. VKT Pharma's approval covered both 150 mg and 300 mg reformulated tablets in the United States. That approval gives the U.S. relaunch access to both commercially important strengths. The Ranitidine industry may therefore see more high-dose demand where approved supply reaches hospital and prescription channels.

Tablets accounted for 61.82% of the ranitidine market in 2025 because oral solids remain practical for outpatient and hospital dispensing. Their established use supports broad availability in retail and institutional pharmacies. Syrup serves a separate role for children and older patients who cannot comfortably use tablets. Ranitidine oral solution is labeled at 15 mg/mL in the U.S. drug information. Weight-based dosing and swallowing problems help maintain this liquid niche. The ranitidine market retains a need for several dosage forms rather than a tablet-only supply model.

Injections are forecast to expand at a 4.82% CAGR from 2026 to 2031. Intravenous use supports stress ulcer prophylaxis, aspiration-risk management before anesthesia, and selected intensive care needs. These patients may not be able to take medicines through the digestive tract. A 2025 study described continued use of parenteral acid suppression protocols for high-risk surgical populations. Hospitals must still apply current guidance on appropriate use and avoid unnecessary prophylaxis. The Ranitidine industry uses this hospital setting as a more specialized source of demand.

Complete Report Scope:

• By Strength
  • 75 mg
  • 150 mg
  • 300 mg
• By Form
  • Tablet
  • Syrup
  • Injection
• By Route of Administration
  • Oral
  • Intravenous
• By Application
  • Gastroesophageal Reflux Disease
  • Peptic Ulcer Disease
  • Zollinger-Ellison Syndrome
  • Erosive Esophagitis
  • Stress Ulcer Prophylaxis
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By End User
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.23% of the ranitidine market in 2025 and retained the largest regional position in 2026. FDA approval of VKT Pharma's reformulated tablets reopened U.S. prescription access after the 2020 withdrawal. Recovery is likely to remain measured because the product is prescription-only and has a 90-day post-opening discard requirement. Many prescribers are also familiar with famotidine, which is used in over-the-counter Zantac 360. Canada and Mexico maintain a generic supply, while price-sensitive hospital purchasing supports use in Mexico.

Europe operates under a divided regulatory setting because the European Union suspension of ranitidine medicines remains in place. This framework has directed much acid suppression care toward proton pump inhibitors and famotidine. Germany resolved supply shortfalls for Ranitidin AbZ 150 mg tablets and Ranitidin-ratiopharm 300 mg tablets in December 2025. The ranitidine market has only limited activity in Spain and other smaller European markets. The United Kingdom, France, and Italy retain residual prescription supply for specific patient populations under national programs. European demand remains constrained by compliance requirements and national authorization pathways.

Asia-Pacific is forecast to grow at a 5.29% CAGR through 2031, making it the fastest-growing region in the ranitidine market. India and China had the largest incident GERD burdens reported in the supplied evidence base. Indian bulk-drug clusters supply active pharmaceutical ingredients to global formulation markets. Domestic production incentives introduced in 2025 reinforce this manufacturing base. South Korea and Japan retain prescription demand in hospital pharmacy channels, while physician familiarity with proton pump inhibitors limits broader uptake. Australia follows a suspended ranitidine framework similar to the European Union. The Middle East and Africa source cost-competitive generic supply largely from Indian manufacturers, while Brazil and Argentina sustain public-formulary demand under tighter nitrosamine monitoring.

1. Apotex
2. Aurobindo Pharma
3. Boehringer Ingelheim
4. Cipla
5. Dr. Reddy's Laboratories Ltd.
6. GlaxoSmithKline
7. Glenmark Pharmaceuticals
8. Granules India
9. Hikma Pharmaceuticals
10. J B Chemicals and Pharmaceuticals Limited
11. Lupin
12. Merck
13. Sanofi
14. Sandoz Group AG
15. Strides Pharma Science
16. Sun Pharmaceuticals Industries
17. Teva Pharmaceutical Industries
18. Tocris Bioscience
19. Viatris
20. Zydus Lifesciences Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising GERD and Peptic Ulcer Burden
  • 4.2.2 Preference for Low-Cost Acid Suppression in Price-Sensitive Markets
  • 4.2.3 Established Oral Dosage Familiarity in Hospital and Retail Formularies
  • 4.2.4 Reformulated Products and Impurity-Control Capabilities Reopening Selected Demand Pools
  • 4.2.5 Pediatric and Geriatric Liquid-Dosing Needs in Selected Care Settings
  • 4.2.6 Short-Course Procurement Preference in Acute Care and Stock-Buffering by Buyers
• 4.3 Market Restraints
  • 4.3.1 NDMA Recall Legacy and Persistent Trust Deficit
  • 4.3.2 Substitution by PPIs and Famotidine-Based Alternatives
  • 4.3.3 Compliance, Testing, and Batch-Release Cost Burden
  • 4.3.4 Stability, Packaging, and Cold-Chain Sensitivity in Reformulated Supply
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Strength
  • 5.1.1 75 mg
  • 5.1.2 150 mg
  • 5.1.3 300 mg
• 5.2 By Form
  • 5.2.1 Tablet
  • 5.2.2 Syrup
  • 5.2.3 Injection
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Intravenous
• 5.4 By Application
  • 5.4.1 Gastroesophageal Reflux Disease
  • 5.4.2 Peptic Ulcer Disease
  • 5.4.3 Zollinger-Ellison Syndrome
  • 5.4.4 Erosive Esophagitis
  • 5.4.5 Stress Ulcer Prophylaxis
• 5.5 By Distribution Channel
  • 5.5.1 Hospital Pharmacies
  • 5.5.2 Retail Pharmacies
  • 5.5.3 Online Pharmacies
• 5.6 By End User
  • 5.6.1 Hospitals
  • 5.6.2 Clinics
  • 5.6.3 Ambulatory Surgical Centers
  • 5.6.4 Home Care Settings
• 5.7 By Geography
  • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
  • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
  • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
    • 5.7.3.4 Australia
    • 5.7.3.5 South Korea
    • 5.7.3.6 Rest of Asia-Pacific
  • 5.7.4 Middle East & Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East & Africa
  • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Apotex Inc.
  • 6.3.2 Aurobindo Pharma Limited
  • 6.3.3 Boehringer Ingelheim International GmbH
  • 6.3.4 Cipla Limited
  • 6.3.5 Dr. Reddy's Laboratories Ltd.
  • 6.3.6 GlaxoSmithKline plc
  • 6.3.7 Glenmark Pharmaceuticals Limited
  • 6.3.8 Granules India Limited
  • 6.3.9 Hikma Pharmaceuticals PLC
  • 6.3.10 J B Chemicals and Pharmaceuticals Limited
  • 6.3.11 Lupin Limited
  • 6.3.12 Merck KGaA
  • 6.3.13 Sanofi
  • 6.3.14 Sandoz Group AG
  • 6.3.15 Strides Pharma Science Limited
  • 6.3.16 Sun Pharmaceutical Industries Limited
  • 6.3.17 Teva Pharmaceutical Industries Ltd.
  • 6.3.18 Tocris Bioscience
  • 6.3.19 Viatris Inc.
  • 6.3.20 Zydus Lifesciences Limited

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment